Ultragenyx Pharmaceutical INC 8-K filings

Ultragenyx has been granted Breakthrough Therapy Designation by the FDA for setrusumab (UX143) to treat osteogenesis imperfecta, based on promising clinical trial results.

Ultragenyx's UX701 gene therapy demonstrates positive clinical activity and improvements in copper metabolism in a Phase 1/2/3 study for Wilson disease, with some patients tapering off standard-of-care treatments.

Ultragenyx announced a 36% year-over-year increase in total revenue for the second quarter of 2024, driven by strong sales of Crysvita and Dojolvi, and raised its full-year revenue guidance.

Ultragenyx has successfully completed an end-of-Phase 2 meeting with the FDA, securing alignment on the design for its pivotal Phase 3 study of GTX-102 for Angelman syndrome.

Ultragenyx Pharmaceutical Inc. held its annual meeting on June 18, 2024, where stockholders approved an amended incentive plan, elected Class II directors, and ratified the selection of an independent accounting firm.

Ultragenyx Pharmaceutical Inc. has entered into an underwriting agreement for a public offering of common stock and pre-funded warrants, expected to generate approximately $330.7 million in net proceeds.

Ultragenyx has reached an agreement with the FDA that cerebral spinal fluid heparan sulfate can be used as a surrogate endpoint to support accelerated approval of its gene therapy, UX111, for Sanfilippo syndrome.

Ultragenyx and Mereo BioPharma reported positive 14-month results from a Phase 2 study showing setrusumab significantly reduced fractures and improved bone mineral density in patients with osteogenesis imperfecta.

Ultragenyx announced positive topline results from its Phase 3 GlucoGene study, showing a significant reduction in cornstarch intake for patients with Glycogen Storage Disease Type Ia treated with DTX401.

Ultragenyx announced its first quarter 2024 financial results, reporting $109 million in total revenue and reaffirming its full-year revenue guidance, while also providing updates on its clinical programs.

Ultragenyx reported promising results from its Phase 1/2 study of GTX-102 for Angelman syndrome, showing rapid and sustained improvements in multiple domains.

Ultragenyx announced a 20% increase in total revenue for 2023, reaching $434 million, and provided a positive outlook for 2024 with multiple clinical trial milestones expected.